Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...
CRISPR Therapeutics (NASDAQ:CRSP) used a fireside chat at TD Cowen’s 46th Annual Healthcare Conference to outline how the ...
Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...
CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.
One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...
Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiationSAN FRANCISCO and BERLIN, ...
Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...
CRISPR gene therapy Casgevy can nearly eliminate sickle cell crises, but difficult stem‑cell collection is delaying access ...
The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
CRISPR-based therapy is a transformative approach to medicine that allows for targeted changes to the genome by directly addressing the source of disease, or to the epigenome through silencing of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results